Evidence map›Paper›PMID 26380105›Full record

ArticleIranian Red Crescent medical journal2015

Expression and Purification of the Recombinant Cytochrome P450 CYP141 Protein of Mycobacterium Tuberculosis as a Diagnostic Tool and Vaccine Production.

Reza Heidari, Mohammad Rabiee-Faradonbeh, Davood Darban-Sarokhalil, Amirhooshang Alvandi, Narges Abdian, Ehsan Aryan, Neda Soleimani, Abolfazl Gholipour

Open access · hybridAbstract read
In one paragraph

Article in Iranian Red Crescent medical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Reza HeidariDepartment of Microbiology and Immunology, Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, IR Iran.
Mohammad Rabiee-FaradonbehDepartment of Microbiology, Shahrekord Branch, Islamic Azad University, Shahrekord, IR Iran.
Davood Darban-SarokhalilDepartment of Microbiology and Immunology, Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, IR Iran.
Amirhooshang AlvandiDepartment of Microbiology, Kermanshah University of Medical Sciences, Kermanshah, IR Iran.
Narges AbdianCellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, IR Iran.
Ehsan AryanAntimicrobial Resistance Research Center, Department of Medical Microbiology, Mashhad University of Medical Sciences, Mashhad, IR Iran.
Neda SoleimaniDepartment of Pathology, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, IR Iran.
Abolfazl GholipourDepartment of Microbiology and Immunology, Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, IR Iran.
Shahrekord University of Medical Sciences · IRIran University of Medical Sciences · IRIsfahan University of Medical Sciences · IRIslamic Azad University of Shahrekord · IRKermanshah University of Medical Sciences · IRMashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTuberculosis (TB) is regarded as a health problem worldwide, particularly in developing countries. Mycobacterium tuberculosis (M. tuberculosis) is the cause of this disease. Approximately two billion people worldwide are infected by M. tuberculosis and annually about two million individuals die in consequence. Forty million people are estimated to die because of M. tuberculosis over the next 25 years if the measures for controlling this infection are not extensively developed. In the vaccination field, Bacillus Calmette-Guérin (BCG) is still the most effective vaccine but it shows no efficacy in adult pulmonary patients. One of the other problems regarding TB is its appropriate diagnosis.

objectivesIn this experimental study, the recombinant cytochrome P450 CYP141 protein of M. tuberculosis was expressed and purified to be used as a vaccine candidate and diagnostic purpose in subsequent investigations. MATERIALS AND

methodsThe optimization of the cytochrome P450 CYP141 protein expression was evaluated in different conditions. Then, this protein was purified with a resin column of nickel-nitrilotriacetic acid and investigated via Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western Blotting.

resultsThe highest expression of the cytochrome P450 CYP141 protein was obtained by the addition of 1 mM of isopropyl β-D-1-thiogalactopyranoside (IPTG) to the bacterial culture grown to an optical density at 600 nm (OD600) of 0.6, 16 hours after induction. This protein was subsequently purified with a purification of higher than 80%. The results of Western Blotting indicated that the purified protein was specifically detected.

conclusionsIn this experimental study, for the first time in Iran the expression and purification of this recombinant protein was done successfully. This recombinant protein could be used as a vaccine candidate and diagnostic purpose in subsequent investigations.

Indexed as

Cytochrome P450 Enzyme SystemGene ExpressionMycobacterium Tuberculosis

Identifiers

PMID26380105
PMCPMC4568075
OpenAlexW1558701067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.